^
    Back
    Association details:
    Biomarker:AR negative
    Cancer:HER2 Negative Breast Cancer
    Drug Class:Aromatase inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Future Oncol
    Title:

    Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancer

    Published date:
    03/01/2022
    Excerpt:
    AR+ tumors were associated with favorable characteristics. AR+ patients had better 5-year recurrence-free survival rates and the risk of recurrence was greater for AR- than for AR+ patients. AR- status predicted the failure of adjuvant endocrine therapy with aromatase inhibitors and of adjuvant chemotherapy with docetaxel plus cyclophosphamide.
    DOI:
    10.2217/fon-2021-1300